Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/30/2025

Association Between Ulcerative Colitis and Pulmonary Embolism

Magnitude of Risk

  • Patients with ulcerative colitis have at least a 2-fold increased risk of venous thromboembolism (VTE), including pulmonary embolism, compared to the general population, with the highest risk occurring during active disease and hospitalization 1, 2
  • UC patients face a 2.0 to 2.85-fold increased risk of VTE compared to healthy controls, with pulmonary embolism being one of the most common manifestations alongside deep vein thrombosis 2, 3
  • The risk of thrombosis-related mortality is doubled in UC patients compared to controls 1, 3, 4
  • Among hospitalized IBD patients undergoing surgery, VTE occurs in 3.3% of UC patients 2
  • VTE-associated mortality is significantly elevated: 37.4 per 1,000 hospitalizations for UC versus 9.9 per 1,000 in non-UC patients (p<0.0001) 2

Pathophysiology and Risk Factors

  • The majority of VTE events occur during active disease phases, as inflammatory activity drives hemostatic alterations that promote thrombosis 1, 3, 4
  • Hospitalization independently increases VTE risk 8-fold in UC patients 1, 5, 4
  • Most VTE events occur in outpatients who have risk factors such as recent hospitalization, surgery, or active disease 2

Clinical Manifestations

  • Deep vein thrombosis and pulmonary embolism are the most common thromboembolic manifestations 1, 3, 4
  • VTE is associated with longer hospitalizations (11.7 vs 6.1 days in non-VTE patients) 2
  • Recurrent VTE is increased in UC patients: 33.4% recur within 5 years after unprovoked first VTE versus 21.7% in non-IBD patients (relative risk 2.5, p=0.001) 2

Prevention Strategies

  • All hospitalized UC patients should receive thromboprophylaxis, particularly those with acute severe disease 1, 5, 2, 6, 4
  • Prophylaxis with low-molecular-weight heparin (LMWH), unfractionated heparin (UFH), or fondaparinux is recommended for all hospitalized UC patients 1, 5, 2, 6, 4
  • Both mechanical thromboprophylaxis and pharmacological prophylaxis should be considered in at-risk patients 1, 3, 4
  • The British Society of Gastroenterology (2025) explicitly states that patients with acute severe UC should receive prophylactic LMWH despite bleeding risk 6

Treatment of Established PE

  • Treatment should follow standard antithrombotic therapy guidelines and is independent of the UC diagnosis 1, 5, 3, 4
  • Anticoagulation should continue for at least 3 months using LMWH, UFH, or fondaparinux initially, followed by vitamin K antagonists 1, 5, 3, 4
  • Long-term anticoagulation should be considered for patients with a second episode of unprovoked VTE 1, 5, 3, 4

Clinical Implications

  • The threshold for investigating VTE should be lower in UC patients, especially those with active disease 2
  • Diagnosis follows standard protocols: ultrasound for DVT, ventilation-perfusion scan or CT pulmonary angiography for PE 1, 2, 3, 4
  • VTE often presents with non-specific symptoms and should be considered in all UC patients with compatible clinical features 2